| Identification | Back Directory | [Name]
Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- | [CAS]
1428247-78-2 | [Synonyms]
IHVR-17028
Propanamide, N-cyclohexyl-2,2-dimethyl-N-[6-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]hexyl]- | [Molecular Formula]
C23H44N2O5 | [MOL File]
1428247-78-2.mol | [Molecular Weight]
428.61 |
| Chemical Properties | Back Directory | [Boiling point ]
617.2±55.0 °C(Predicted) | [density ]
1.15±0.1 g/cm3(Predicted) | [form ]
Oil | [pka]
13.72±0.70(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
IHVR-17028 is a potent and broad-spectrum antiviral agent. IHVR-17028 exhibits antiviral activity against BVDV, TCRV and DENV with EC50 values of 0.4 μM, 0.26 μM, 0.3 μM, respectively. IHVR-17028 is a potent ER α-glucosidase?I?inhibitor with an IC50 of 0.24 μM. IHVR-17028 can be used for infectious diseases research[1][2]. | [in vivo]
In Pharmacokinetic analysis in rats, IHVR17028 (oral gavage; 75 mg/kg) shows a Cmax?value of 0.18 μg/ml; the Tmax value is 1.56 hours; and the F% value is 12% after PO administration, the T1/2 value is 0.88 hour after iv. adminstration[1].IHVR-17028 (oral gavage; 25-50 mg/kg; treatment 1 day prior to virus challenging) exhibits significant protection in mouse model of lethal MARV infection[1]. | Animal Model: | BALB/c mice are challenged with 1,000 PFU mouse adapted MARV via IP injection[1] | | Dosage: | 50 mg/kg | | Administration: | Treatment 1 day prior to virus challenging | | Result: | Exhibited protection in mouse when the treatment is initiated 1 day prior to virus challenging. |
| Animal Model: | C57B1/6 mice challenged with 1,000 PFU mouse adapted EBOV[1] | | Dosage: | 25 mg/kg | | Administration: | Twice daily at 12 h interval; starting 4 h post infection for 10 days | | Result: | Inhibited EBOV infection in mice. |
| [References]
[1] Jinhong Chang, et al. Small molecule inhibitors of ER α-glucosidases are active against multiple hemorrhagic fever viruses.Antiviral Res. 2013 Jun;98(3):432-40. DOI:10.1016/j.antiviral.2013.03.023 |
|
|